SUPERNEWS - NYSE:GSK (GSK plc) Stock Price, News, Quote, History

SUPERNEWS

Equities

Top Stories

GSK, Others Await Zantac Ruling Amid $45B Liability Concerns

4/24, 08:30 EDT

GSK Receives Upgrade to Buy, Ferrari Downgraded to Sell

GSK Upgraded on Vaccine Growth Prospects; Ferrari Downgraded Due to Valuation Concerns

3/4, 06:08 EST

GSK's Stock Wobbles Amid Zantac Litigation Drama

The share price of the company in question experienced a significant drop in 2022, which aligns with the timeline of the Zantac-related legal developments and the subsequent investor reaction to the potential liabilities faced by the pharmaceutical companies involved. - Following the initial plunge, the share price has shown signs of recovery throughout 2023, yet it has not returned to its pre-drop levels, indicating ongoing investor concern regarding the outcome of the litigation and its impact on the company's financial health.

4/24, 08:29 EDT

Analysts Upgrade GSK and Nvidia with Positive Outlooks

Citi upgrades GSK to 'buy' with a £21 target; UBS raises Nvidia's target to $850, highlighting strong AI demand.

2/13, 06:01 EST

Wall Street Analysts Upgrade Disney, Dutch Brothers, and GSK, Citing Strong Growth Potential

Morgan Stanley, Piper Sandler, Guggenheim, and Baird issue bullish calls on Disney, Dutch Brothers, GSK, and Squarespace, citing growth and profitability.

3/4, 08:39 EST

GSK, Others Await Zantac Ruling Amid $45B Liability Concerns

4/24, 08:30 EDT

GSK Receives Upgrade to Buy, Ferrari Downgraded to Sell

3/4, 06:08 EST

GSK's Stock Wobbles Amid Zantac Litigation Drama

4/24, 08:29 EDT

GSK News

Microsoft Closes Nigeria Hub, Affects 100+ Amid Crisis

5/8, 05:24 EDT

Guangdong Eyes GLP China Stake, Valuation at $6.9B

4/30, 01:45 EDT

Novo, Stellantis Eye Gains in EMEA Amid Market Tests

4/26, 05:22 EDT

GSK, Others Await Zantac Ruling Amid $45B Liability Concerns

4/24, 08:30 EDT

GSK's Stock Wobbles Amid Zantac Litigation Drama

4/24, 08:29 EDT

Heineken's Nigeria Breweries Closes 2 Plants Amid $94M Loss

4/17, 09:01 EDT

FTSE 100 Hits Record High on Rate Cut Optimism

4/2, 05:08 EDT

Tragic Death of Vice Admiral Robert Walmsley Unveils Family Dispute and Unresolved Questions

3/31, 05:51 EDT

Copper Futures Hit Record, Speculation Sparks Surge

3/20, 23:55 EDT

Jefferies Spots 'Hidden Gem' Health Stocks with Growth Potential

3/20, 07:42 EDT

UBS Unveils High Conviction Picks with 90% Upsides

3/19, 19:33 EDT

Nigeria's Naira Plummets 70%, Economic Reforms Tested

3/9, 06:48 EST

Cheap Stocks Poised for Rebound, Analysts Suggest

3/6, 13:34 EST

Undervalued Stocks Like Johnson & Johnson and Alphabet Recommended Amid Market Highs

3/6, 13:33 EST

Wall Street Analysts Upgrade Disney, Dutch Brothers, and GSK, Citing Strong Growth Potential

3/4, 08:39 EST

GSK Receives Upgrade to Buy, Ferrari Downgraded to Sell

3/4, 06:08 EST

Are GRANOLAS Stocks the Future of European Market Leadership?

2/29, 18:55 EST

Global Analysts Embrace "Magnificent" Trend Beyond US Tech Giants

2/28, 04:49 EST

Morningstar Spots Bargains: Kraft Heinz, Medtronic, GSK Shine

2/19, 19:45 EST

Analysts Upgrade GSK and Nvidia with Positive Outlooks

2/13, 06:01 EST

European GRANOLAS Match Tech Titans in Market Performance, Offering Lower Volatility and Attractive Valuation

2/12, 04:41 EST

Bristol Myers' Earnings Beat Sparks Future Growth Optimism

2/6, 10:31 EST

Aiolos Bio Buyout: GSK's Respiratory Market Play

1/9, 22:34 EST

Wall Street Views

Chief Markets Strategist at Morningstar

David Sekera, 2/19/24

GSK

KHC

MDT

“It’s always a stock picker’s market, but that this is even more pertinent this year. We can look at individual stocks across several themes over the past couple of years to see which stocks have really been the ones that have outperformed the broader market,”

“The company’s individual costs went up over the past couple of years as inflation was running at a very high rate in the United States. And, to some degree, it lagged in its own price increases,”

“As inflation now is moderating, we do think that their price increases can catch up to their costs and get back towards more normalized to historical margins.”

“Medtronic is a four-star rated stock, trades at a 25% discount, it’s a high-quality company. And our equity team thinks it’s probably one of the best positioned med tech companies, for the continued aging of the baby boomer generation,”

“The London Stock Exchange-listed company is trading at a 27% discount...the Morningstar team thinks that the market is probably overestimating the litigation costs to the company for one of its products by the name of Zantac,”